Halbjahreszahlen von ATIS - 500 Beiträge pro Seite

[Cpt.Hills]

Hier die aktuellen Q-/HJ-Zahlen von ATIS:

http://www.quicken.com/investments/news/story/pr/?story=/new…

Die Umsätze mit Dermagraft und TransCyte(TM) sehen ja gar nicht so schlecht aus.

Und das milestone payment kann man ja rausrechnen.

LA JOLLA, Calif., Aug. 7 /PRNewswire/ -- Advanced Tissue Sciences, Inc. (Nasdaq: ATIS, news,
msgs) today announced its financial results for the quarter ended June 30, 2000. Total revenues were
$6.3 million for the three months ended June 30, 2000 compared to $11.1 million for the three months
ended June 30, 1999. Total revenues were $13.7 million for the six months ended June 30, 2000
compared to $22.0 million for the six months ended June 30, 1999. The Company reported a net loss
to common stockholders for the three months ended June 30, 2000 of $7.4 million or $0.12 per share
compared to $5.1 million or $0.11 per share for the three months ended June 30, 1999. The Company
also reported a net loss to common stockholders for the six months ended June 30, 2000 of $15.8
million or $0.27 per share compared to $10.7 million or $0.25 per share for the six months ended June
30, 1999.

The decrease in revenues in the three and six-month periods ended June 30, 2000 as compared to the
corresponding period in 1999 principally reflects the recognition in the three and six-month periods
ended June 30, 1999 of $4.4 million and $9.4 million, respectively, of a $15 million milestone payment
received in January 1999 from Smith & Nephew associated with the expansion of the Dermagraft Joint
Venture. These payments were recognized into revenues in 1999 as the related financial commitments
were met. This decrease was partially offset by the recognition of $0.9 million and $1.8 million,
respectively, in the three and six-month periods ended June 30, 2000 of licensing payments previously
received from Inamed Corporation in 1999.

Separately, the Dermagraft Joint Venture reported sales of TransCyte(TM) and Dermagraft(R) to
customers of $996,000 for the three months ended June 30, 2000 compared to $561,000 in the three
months ended June 30, 1999. Combined sales for TransCyte and Dermagraft for the six months ended
June 30, 2000 totaled $1.7 million compared to sales of $1.0 million for the six months ended June 30,
1999. TransCyte sales were $1.6 million of the total sales reported for the six months ended June 30,
2000 as compared to $0.9 million for the six months ended June 30, 1999.

"Consistent with our business strategy of developing a broad portfolio of products to enhance human
healing, we continue to advance programs in each of our four areas of therapeutic focus," said Arthur J.
Benvenuto, Chairman and Chief Executive Officer of Advanced Tissue Sciences. "As recently
announced, enrollment in the clinical trial of Dermagraft for the treatment of diabetic foot ulcers has
been completed and we currently expect to submit a Pre-Market Approval (PMA) application to the
Food and Drug Administration (FDA) by the end of the summer. In addition, activities related to
launching the multi-partner consortium lead by the University of Washington to grow functional heart
tissue have been initiated. As previously reported, this project is being funded by a grant from the
National Institutes of Health, and our patented technology will play a key role in the project."

As of June 30, 2000, the Company had cash, cash equivalents and short-term investments of
approximately $23 million.

Warten wir`s ab, gestern abend sind die Zahlen ja schon mal gut aufgenommen worden.

cu

Hills

[slagfidr]

Danke Dir Hills für die Info s!

Ist ja z.Z. leider nicht viel los hier im Advanced Tissue Thread.
Um so schöner mal wieder was neues und positives zu erfahren!

Sei gegrüßt

Slagfidr

[Ohne.Moos.nix.los]

Ja, danke. Endlich mal wieder News.

Von sfz kommt ja leider nichts mehr. Ist wahrscheinlich mit anderem beschäftigt.
Wie seht Ihr die Entwicklung der Aktie?

Viele Grüße

OMNL